PD L1 News and Research

RSS
Monoclonal antibody nivolumab improves survival rates of melanoma patients

Monoclonal antibody nivolumab improves survival rates of melanoma patients

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Targeting PD-1/PD-L1 signaling may open up new therapy options for lung cancer patients

Targeting PD-1/PD-L1 signaling may open up new therapy options for lung cancer patients

New drug combination shows promise in patients with metastatic melanoma

New drug combination shows promise in patients with metastatic melanoma

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences announces record-setting revenue for 2014

Caris Life Sciences announces record-setting revenue for 2014

PD-L1 expression tied to favourable prognosis in SCLC

PD-L1 expression tied to favourable prognosis in SCLC

PD-1, PD-L1 differentially expressed in NSCLC

PD-1, PD-L1 differentially expressed in NSCLC

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

Nivolumab drug highly effective for Hodgkin's lymphoma

Nivolumab drug highly effective for Hodgkin's lymphoma

Oncologists examine efficacy of rose bengal against cancer

Oncologists examine efficacy of rose bengal against cancer

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

Immune-suppressing protein may predict how patients respond to treatment

Immune-suppressing protein may predict how patients respond to treatment

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

Protein complex plays key role in detecting tumor cells, promotes anti-tumor response

Protein complex plays key role in detecting tumor cells, promotes anti-tumor response

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.